| Patient | Muhammad Ali |
|---|---|
| Date of birth | 1972-01-17 |
| Identifiers | MRN HR-BX001-SYN; SSN (made up) 000-01-7724 |
| Document date | 2026-02-10 |
| Author | Celeste Moreau, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Young-onset Parkinson's disease, diagnosed twelve years ago at 42, in a 54-year-old man whose slowness of movement now limits daily tasks on a modest levodopa dose. Please review the diagnosis, advise on the levodopa dose or another agent, and plan rehabilitation for his soft speech and gait. [S]
Urgency: Routine, within four weeks, on the same day as his four-week primary care check. [S]
Questions for the consultant:
Parkinsonism diagnosed at 42, three years after he retired from professional boxing; at the time it was described as a parkinsonian syndrome possibly related to repeated head blows, and that link has never been settled. On carbidopa-levodopa 25/100 mg one tablet three times daily, often taken with meals, for many years. Today, in the on state: MDS-UPDRS Part III 30, Hoehn and Yahr stage 2.5, with bilateral bradykinesia and rigidity worse on the right, right-hand rest tremor, reduced facial expression and blinking, and soft, monotone speech. No dyskinesia, wearing-off, or freezing. No falls; Timed Up and Go 13 seconds; recovers after three steps on the pull test. Blood pressure 130/80 mmHg supine and 122/78 mmHg standing at 3 minutes. MoCA 27 of 30, PHQ-9 3, EAT-10 2, negative REM sleep behavior disorder and impulse-control screens, and Epworth score 6. Blood count, chemistry, vitamin B12, and TSH normal. No dopamine-blocking drugs [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
3 later historical claims are omitted because they describe events after the index age. See the teaching note.
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Carbidopa-levodopa 25/100 mg oral tablet, one tablet by mouth three times daily | One tablet by mouth three times daily, at about 7 a.m., noon, and 5 p.m. | Oral route | 2014-10-01 to 2026-03-10 | completed | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Parkinson's disease, young onset (diagnosed at 42), Hoehn and Yahr stage 2.5, without dyskinesia or motor fluctuations | active | confirmed | G20.A1 | S — Synthetic modern coding of the publicly disclosed diagnosis; the stage and the absence of motor complications are synthetic. |
| Hypokinetic dysarthria with soft speech due to Parkinson's disease | active | confirmed | R47.1 | S — Synthetic modern coding of the publicly reported speech difficulty; the severity is synthetic. |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1981 | Professional boxing career with repeated blows to the head, ended by retirement in 1981; whether it caused his Parkinson's disease is disputed | R (CLM-0003, CLM-0006) |
| 1984 | Parkinsonian condition diagnosed in 1984, at 42, by a neurologist in New York, with slowness of movement, a masked face, decreased blinking, tremor, and a shuffling gait | D (CLM-0003, CLM-0004) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-10 | Body height | 191 | cm | S |
| 2026-02-10 | Body weight | 102 | kg | S |
| 2026-02-10 | Body mass index (BMI) [Ratio] | 28 | kg/m2 | S |
| 2026-02-10 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-02-10 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-02-10 | Heart rate | 72 | /min | S |
| 2026-02-10 | Respiratory rate | 14 | /min | S |
| 2026-02-10 | Body temperature | 36.7 | Cel | S |
| 2026-02-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-10 | Hemoglobin [Mass/volume] in Blood | 14.6 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-02-10 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-02-10 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-02-10 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-02-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 87 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-02-10 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-02-10 | Calcium [Mass/volume] in Serum or Plasma | 9.5 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-02-10 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 512 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-02-10 | Thyrotropin [Units/volume] in Serum or Plasma | 1.8 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-02-10 | Total score [MoCA] | 27 | {score} | S | ||
| 2026-02-10 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |